Twitxy Saved

S Blitshteyn MD, FAAN, FANA, Dysautonomia Clinic

Verified account This account is verified. Learn more

@dysclinic

Neurologist/Researcher, Director of #Dysautonomia Clinic, Clinical Associate Professor @Jacobs_Med_UB. Trained @MayoClinic. Tweets🚫med advice. Opinions my own.
Buffalo, NY dysautonomiaclinic.com Joined July 2019
1.7K Following 23K Followers 8.7K Posts

Latest posts 5

Pinned post

S Blitshteyn MD, FAAN, FANA, Dysautonomia Clinic Verified account @dysclinic
I am incredibly honored to have been invited to talk about #LongCovid and #Dysautonomia by the brilliant @EricTopol on his Ground Truths podcast. It's amazing to achieve this despite all of the obstacles in my life. 🙏🧠👩‍🔬

@Jacobs_Med_UB @AANmember @DrABrashear #BrainHealth
Eric Topol Verified account @EricTopol May 20, 2024
Pearls on #dysautonomia, #LongCovid, #POTS from a leading expert on the front lines, Dr. Svetlana Blitshteyn
@dysclinic
In the new Ground Truths (link in profile)
View quoted post on X
45 replies 88 reposts 485 likes 102K views View on X
S Blitshteyn MD, FAAN, FANA, Dysautonomia Clinic Verified account @dysclinic
🚨 Finally, after a lot of back-and-forth, my paper on why psychotherapies SHOULD NOT be used as standard treatment for #POTS, is published!

Key points:
🧠 There is NO scientific evidence that mind-body, CBT, neuroplasticity, etc. therapies are effective for treatment of POTS symptoms.
🧠 Promoting psychotherapies without evidence-based data inadvertently creates further barriers to patient care (see figure below).
🧠 This paper does not argue against psychotherapies, psychologists or psychiatrists: it argues to implement these therapies for patients who truly need them: those with comorbid mood disorders, psychological issues, poor coping mechanisms, medical trauma, etc - not "everyone with POTS."

Clinical observation: Patients with POTS are commonly treated with antidepressants and psychotherapies, but my 2 papers highlight that there is NO scientific evidence that either of those treatments work for POTS.

Clinical practice: Clinicians should use standard therapies (salt, fluids, beta blockers, midodrine, ivabradine, etc) to treat POTS. Antidepressants and psychotherapies are NOT standard therapies.
frontiersin.org/journals/neuro…
13 replies 71 reposts 222 likes 5.7K views View on X
S Blitshteyn MD, FAAN, FANA, Dysautonomia Clinic Verified account @dysclinic
Monday before the Thanksgiving week is always busy, but I managed to squeeze in 2 very productive meetings: one with Drs. @PutrinoLab and Cheng and a 2nd with some of my research team people who are working hard to get #dysautonomia research done! Dr. Sherry Zimmermann, with #GoBills box behind her 😃, is our @dysclinic's research coordinator.
0 replies 0 reposts 43 likes 1.1K views View on X
S Blitshteyn MD, FAAN, FANA, Dysautonomia Clinic Verified account @dysclinic
Very excited to start as a PI at @Jacobs_Med_UB on the upcoming Phase 3 trial of baloncibart, an NPR1-blocking monoclonal antibody, for #POTS! If you want to participate at our Western New York site, follow me for a recruitment announcement, coming soon.
biospace.com/drug-developme…
www.biospace.com Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial Regeneron’s mid-stage success in postural orthostatic tachycardia syndrome has the company gearing up to launch a Phase 3 study in the first half of 2027.
5 replies 23 reposts 93 likes 2.4K views View on X
S Blitshteyn MD, FAAN, FANA, Dysautonomia Clinic Verified account @dysclinic
📢 I want to clarify that even if IV saline is used as a comparator, that's OK. You can follow 3 cohorts: IVIG, IV saline and "standard of care" over 6-9 months (3 months may be too soon to tell), and then assess
✔️self-reported symptoms
✔️10-min stand test/tilt table test AND
✔️a skin biopsy for small fiber neuropathy (SFN).
✔️Let's see how these 3 cohorts fair over a period of 9 months!

💉 The other issue is inclusion/exclusion criteria. Who got in? Who should've gotten in:
✔️confirmed POTS+SFN patients with
✔️some type of positive autoimmune marker or ✔️comorbid autoimmune disorder.
✔️That's the population that may benefit the most from IVIG/SCIG.

‼️ Conclusion:
✔️The jury is still out on IVIG/SCIG even with negative results of the NIH-RECOVER trial.
✔️As I keep saying, IVIG+SCIG should be available and accessible to severe, treatment-refractory patients who exhausted all other therapies.

For more on IVIG, read these 3 papers:
nature.com/articles/s4159…

frontiersin.org/journals/cellu…

ovid.com/jnls/americant…
www.nature.com The effect of high-dose long-term therapy of intravenous immunoglobulins in autoimmune autonomic... Scientific Reports - The effect of high-dose long-term therapy of intravenous immunoglobulins in autoimmune autonomic and sensory small fiber neuropathy: a retrospective open-label controlled study
📢 BREAKING NEWS: It was announced today that the NIH-RECOVER Autonomic trial of IVIG in 200 patients with post-COVID POTS vs. IV saline showed "no significant impact of IVIG on symptoms of severe POTS."

Details of the trial are not available yet, but results are a major setback for patients with disabling post-COVID POTS waiting for treatment.
recovercovid.org/news/latest-re…
View quoted post on X